目的 探讨阿立哌唑口崩片联合盐酸度洛西汀肠溶片治疗抑郁症的临床疗效。方法 选取2015年3月-2019年8月天津市安宁医院收治的96例抑郁症患者为研究对象，所有研究对象随机分为对照组和治疗组，每组各48例。对照组患者口服盐酸度洛西汀肠溶片，40~60 mg/d（根据患者的病情、耐受性调整药物剂量），1次/d；治疗组患者在对照组患者治疗的基础上口服阿立哌唑口崩片，5~10 mg/d（根据患者的病情及耐受性调整药物剂量），1次/d。两组患者均接受8周治疗。观察两组的临床疗效，比较两组的睡眠质量、HAMD评分和血清甲状腺素水平。结果 治疗后，对照组、治疗组的总有效率分别为83.33%、95.83%，两组患者的临床疗效有显著差异（P<0.05）。治疗后，两组患者的入睡时间、S1+S2时间均显著缩短，实际睡眠时间、REM、S3+S4时间以及睡眠效率均明显升高，差异有统计学意义（P<0.05）；且治疗组患者的入睡时间、S1+S2时间均明显短于对照组，实际睡眠时间、REM、S3+S4时间以及睡眠效率均明显高于对照组，差异有统计学意义（P<0.05）。治疗后，两组患者的HAMD评分均显著降低（P<0.05），且治疗8周后，治疗组的HAMD评分明显低于对照组（P<0.05）。治疗8周后，对照组患者甲状腺素水平显著高于治疗前（P<0.05）；治疗4、8周后，治疗组患者甲状腺素水平显著高于治疗前（P<0.05）；且治疗8周后，治疗组患者的甲状腺素水平明显高于对照组（P<0.05）。结论 阿立哌唑口崩片联合盐酸度洛西汀肠溶片治疗抑郁症患者的临床效果显著，可降低HAMD评分，改善睡眠质量，显著提高患者的甲状腺素水平，且安全性较高，值得推广使用。

Objective To investigate the effect of Aripiprazole Orally Disintegrating Tablets combined with Duloxetine Hydrochloride Enteric-coated Tablets in treatment of depression. Methods Patients (96 cases) with depression in Tianjin Anning Hospital from March 2015 to August 2019 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Duloxetine Hydrochloride Enteric-coated Tablets, 40-60 mg/time (adjusted the dosage according to the patient's condition and tolerance), once daily. Patients in the treatment group were po administered with Aripiprazole Orally Disintegrating Tablets on the basis of the control group, 5-10 mg/time (adjusted the dosage according to the patient's condition and tolerance), once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and sleep quality, HAMD scores, and peripheral blood thyroxine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, sleep time and S1 + S2 time in two groups were significantly shorted, but actual sleep time, REM, S3 + S4 time, and sleep efficiency in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And sleep time and S1 + S2 time in the treatment group were significantly shorter than those in the control group, but actual sleep time, REM, S3 + S4 time, and sleep efficiency in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, HAMD scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And after treatment for 8 weeks, the HAMD scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 8 weeks, the thyroxine level in the control group was significantly increased, and after treatment for 4 and 8 weeks, the thyroxine level in the treatment group was significantly increased, and the difference was statistically significant in the same group (P<0.05). And after treatment for 8 weeks, the thyroxine level in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P<0.05). Conclusion Aripiprazole Orally Disintegrating Tablets combined with Duloxetine Hydrochloride Enteric-coated Tablets has clinical curative effect in treatment of depression, can significantly reduce HAMD scores, improve sleep quality, and improve thyroxine levels, with the safety, which has a certain clinical application.

R971